USE OF GONADOTROPIN-RELEASING HORMONE AGONISTS IN TREATMENT OF RECURRENT PRE-MENSTRUAL ENDOMETRIAL HYPERPLASIA

This article presents modern insights into the pathogenesis of endometrium hyperplastic processes, matrix metalloproteinases and their tissue inhibitors, and their role in development of endometrium hyperplasia. A pathogenetic substantiation is given for use of Lucrin Depot, which affects the key mo...

Full description

Bibliographic Details
Main Authors: Yu. E. Dobrokhotova, L. V. Saprykina, N. A. Litvinova, Yu. N. Zadonskay
Format: Article
Language:Russian
Published: IRBIS LLC 2016-09-01
Series:Акушерство, гинекология и репродукция
Subjects:
Online Access:https://www.gynecology.su/jour/article/view/265
id doaj-c0afc5876fc9415d964a30ae74dfa5b1
record_format Article
spelling doaj-c0afc5876fc9415d964a30ae74dfa5b12021-07-28T13:44:39ZrusIRBIS LLCАкушерство, гинекология и репродукция2313-73472500-31942016-09-01511517263USE OF GONADOTROPIN-RELEASING HORMONE AGONISTS IN TREATMENT OF RECURRENT PRE-MENSTRUAL ENDOMETRIAL HYPERPLASIAYu. E. Dobrokhotova0L. V. Saprykina1N. A. Litvinova2Yu. N. Zadonskay3Department of obstetrics and gynecology of Moscow Faculty of GOU VPO Russian State Medical University of RoszdravDepartment of obstetrics and gynecology of Moscow Faculty of GOU VPO Russian State Medical University of RoszdravDepartment of obstetrics and gynecology of Moscow Faculty of GOU VPO Russian State Medical University of RoszdravDepartment of obstetrics and gynecology of Moscow Faculty of GOU VPO Russian State Medical University of RoszdravThis article presents modern insights into the pathogenesis of endometrium hyperplastic processes, matrix metalloproteinases and their tissue inhibitors, and their role in development of endometrium hyperplasia. A pathogenetic substantiation is given for use of Lucrin Depot, which affects the key molecular mechanisms of development of hyperplastic processes, with the objective of pharmacological correction of this pathologyhttps://www.gynecology.su/jour/article/view/265endometrium hyperplasiamatrix metalloproteinaseslucrin depot
collection DOAJ
language Russian
format Article
sources DOAJ
author Yu. E. Dobrokhotova
L. V. Saprykina
N. A. Litvinova
Yu. N. Zadonskay
spellingShingle Yu. E. Dobrokhotova
L. V. Saprykina
N. A. Litvinova
Yu. N. Zadonskay
USE OF GONADOTROPIN-RELEASING HORMONE AGONISTS IN TREATMENT OF RECURRENT PRE-MENSTRUAL ENDOMETRIAL HYPERPLASIA
Акушерство, гинекология и репродукция
endometrium hyperplasia
matrix metalloproteinases
lucrin depot
author_facet Yu. E. Dobrokhotova
L. V. Saprykina
N. A. Litvinova
Yu. N. Zadonskay
author_sort Yu. E. Dobrokhotova
title USE OF GONADOTROPIN-RELEASING HORMONE AGONISTS IN TREATMENT OF RECURRENT PRE-MENSTRUAL ENDOMETRIAL HYPERPLASIA
title_short USE OF GONADOTROPIN-RELEASING HORMONE AGONISTS IN TREATMENT OF RECURRENT PRE-MENSTRUAL ENDOMETRIAL HYPERPLASIA
title_full USE OF GONADOTROPIN-RELEASING HORMONE AGONISTS IN TREATMENT OF RECURRENT PRE-MENSTRUAL ENDOMETRIAL HYPERPLASIA
title_fullStr USE OF GONADOTROPIN-RELEASING HORMONE AGONISTS IN TREATMENT OF RECURRENT PRE-MENSTRUAL ENDOMETRIAL HYPERPLASIA
title_full_unstemmed USE OF GONADOTROPIN-RELEASING HORMONE AGONISTS IN TREATMENT OF RECURRENT PRE-MENSTRUAL ENDOMETRIAL HYPERPLASIA
title_sort use of gonadotropin-releasing hormone agonists in treatment of recurrent pre-menstrual endometrial hyperplasia
publisher IRBIS LLC
series Акушерство, гинекология и репродукция
issn 2313-7347
2500-3194
publishDate 2016-09-01
description This article presents modern insights into the pathogenesis of endometrium hyperplastic processes, matrix metalloproteinases and their tissue inhibitors, and their role in development of endometrium hyperplasia. A pathogenetic substantiation is given for use of Lucrin Depot, which affects the key molecular mechanisms of development of hyperplastic processes, with the objective of pharmacological correction of this pathology
topic endometrium hyperplasia
matrix metalloproteinases
lucrin depot
url https://www.gynecology.su/jour/article/view/265
work_keys_str_mv AT yuedobrokhotova useofgonadotropinreleasinghormoneagonistsintreatmentofrecurrentpremenstrualendometrialhyperplasia
AT lvsaprykina useofgonadotropinreleasinghormoneagonistsintreatmentofrecurrentpremenstrualendometrialhyperplasia
AT nalitvinova useofgonadotropinreleasinghormoneagonistsintreatmentofrecurrentpremenstrualendometrialhyperplasia
AT yunzadonskay useofgonadotropinreleasinghormoneagonistsintreatmentofrecurrentpremenstrualendometrialhyperplasia
_version_ 1721272139755028480